Compare Adaptive Biotechnologies Corp (ADPT) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Pfizer Inc — how do they compare? Adaptive Biotechnologies Corp trades at $25.5 (market cap $4.04B), while Pfizer Inc trades at $26.42 (market cap $151.73B). The key difference: Pfizer Inc is far larger — about 37.6× Adaptive Biotechnologies Corp's market cap, and Pfizer Inc pays a 6.46% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | PFE | |
|---|---|---|
Market Cap | $4.04B | $151.73B |
Sector | Health | Health |
52-Week High | $25.45 | $28.56 |
52-Week Low | $12.30 | $23.60 |
Enterprise Value | $4.10B | $203.22B |
Volume | — | 29,869,932 |
Dividend Yield | — | 6.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Pfizer (PFE) trades at $27.05, up 1.16% with a bullish technical signal and consistent earnings beats in recent quarters. Revenue remains stable around $62-63 billion, though net income is projected to decline in 2026. The stock shows strong profitability margins and a solid balance sheet, but faces headwinds from patent expirations and competitive pressures.
The outlook is mixed: valuation multiples appear reasonable, and analyst consensus leans hold with a $27.86 target. Key risks include execution on pipeline catalysts and margin compression. Upside depends on successful drug launches and cost management amid a challenging revenue environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
